Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

minnesotafarmcountry Jun. 25 at 4:42 AM

$CADL Back to the AI trade tomorrow? Will biotech traders jump on that bandwagon again and chase at nosebleed valuations? 🤷‍♀️. Too bad for them!

0 · Reply

1Loonie2Toonie Jun. 24 at 11:09 PM

$CADL I wish we were around $15 at this stage. Maybe in a few months...

1 · Reply

Home_Skillet Jun. 24 at 10:28 PM

$CADL I don’t wish this awful disease on anyone. With the rising cause of lung cancer cases this is good for business hopefully CADL can take control of all these people affected by it! While older smokers are still the most affected, about 15% to 20% of all new lung cancer cases globally occur in non-smokers.Young Demographics: Studies indicate that non-smokers who develop lung cancer tend to be diagnosed at a younger age than smokers, with a significant number of cases emerging in young adults and predominantly among women.

0 · Reply

Newageinvestor Jun. 24 at 10:12 PM

$CADL The positive trend continues with another 16 month high (intraday low), and a third day in a row closing above $9. Big day with ALL 1.6mil shares exchanging hands a over $9 dollars a share. Looking forward to seeing how the short interest is progressing. At $9 a share I would imagine that 90%+ are underwater, and if smart, are looking for a way out. With the XBI up 80%+ in a year, the time for for CADL to shine is upon us.

0 · Reply

Clemente4141 Jun. 24 at 9:56 PM

$CADL

0 · Reply

bad_at_stocks Jun. 24 at 9:49 PM

$CADL eventually for a stock to work it has to go up, but i'd be lying if i told you i don't miss the good old days of $4.50 per share and freddie and poppie bear cases that would make an insane lunatic go "woah buddy lay off the pcp pipe". personal opinion only, not investment advice.

3 · Reply

paladinten17 Jun. 24 at 9:35 PM

$CADL / 🕯️ Come on baby light my fire Come on baby light my fire Try to set the night on, fire yeah The time to hesitate is through No time to wallow in the mire Try now we can only lose And our love become a funeral pyre https://music.apple.com/us/album/light-my-fire/1715722455?i=1715722825

1 · Reply

ShowMeThaMonay Jun. 24 at 9:27 PM

$CADL hard to tell what to do, don’t really want to add shares here. Have buys set if it drops back to 8.30 and lower. I added some long calls that I’m holding.

0 · Reply

CO145 Jun. 24 at 9:14 PM

$CADL 65,000 RT x 30% share + 65,000 RP x 10% share x $200K cost = $5.2B Peak x 4x = $20B. What BP does not want $5.2B in sales, which maybe low if a greater percent of the RP population opt for can-2409. This is potentially a mega blockbuster opportunity and may even fall into the Elite franchise class if penetration is greater or other indications come to market. Under $700M now is absolutely insane.

2 · Reply

DiamondDog33 Jun. 24 at 9:12 PM

$CADL AS THE DOG STATED ON FRIDAY with UNUSUAL VOL ... BUTTLOAD OF STOCK OPTIONS GRANT 9.08 .... 7 MGRS BOARD .... AH BUT something else happened too ...digging. ....We will see how JULY AUG SEPT pans out in the (dead period) ....< ....8.00 bottom ..but after Lung PR coming .....short boost at best after recent run....she may revisit before the Biggie....May touch 10 and pull a yank.

2 · Reply

Candel Therapeutics Transcript: AGM 2026

Jun 3, 2026, 5:30 PM EDT - 21 days ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-02T14:27:23.000Z - 22 days ago

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

Jun 2, 2026, 8:05 AM EDT - 22 days ago

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Jun 1, 2026, 4:05 PM EDT - 23 days ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2026, 10:00 AM EDT - 5 weeks ago

Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

2026-05-18T19:30:09.000Z - 5 weeks ago

Candel Therapeutics price target raised to $9 from $7 at BofA

May 15, 2026, 4:05 PM EDT - 5 weeks ago

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

May 15, 2026, 1:00 PM EDT - 5 weeks ago

Candel Therapeutics Transcript: Study result

May 15, 2026, 1:00 PM EDT - 5 weeks ago

Candel Therapeutics Slides: Study result

May 15, 2026, 1:00 PM EDT - 5 weeks ago

Candel Therapeutics Press release: Study result

May 14, 2026, 8:05 AM EDT - 5 weeks ago

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Candel Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Candel Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 5 weeks ago

Candel Therapeutics Slides: Corporate presentation

May 13, 2026, 8:05 AM EDT - 6 weeks ago

Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Candel Therapeutics Slides: Corporate presentation

May 4, 2026, 8:05 AM EDT - 7 weeks ago

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Apr 29, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Candel Therapeutics Proxy statement: Proxy filing

2026-04-20T10:42:20.000Z - 2 months ago

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald

Apr 14, 2026, 7:00 AM EDT - 2 months ago

Candel Therapeutics Slides: Corporate presentation

2026-03-18T10:22:07.000Z - 3 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-17T12:22:09.000Z - 3 months ago

Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC

Mar 17, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Slides: Corporate presentation

2026-03-13T10:45:12.000Z - 3 months ago

Candel Therapeutics price target lowered to $22 from $24 at Citi

2026-03-12T12:11:41.000Z - 3 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:01.000Z - 3 months ago

Candel Therapeutics sees cash runway into 1Q28

Mar 12, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Annual report: Q4 2025

Mar 9, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Mar 3, 2026, 11:50 AM EST - 4 months ago

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:05 AM EST - 4 months ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

2026-02-20T03:25:29.000Z - 4 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 4 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

Feb 19, 2026, 9:40 PM EST - 4 months ago

Candel Therapeutics Announces Pricing of Public Offering

2026-02-19T22:10:17.000Z - 4 months ago

Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T21:13:42.000Z - 4 months ago

Candel Therapeutics announces $100M common stock offering

Feb 19, 2026, 4:05 PM EST - 4 months ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 4 months ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026, 8:05 AM EST - 4 months ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Dec 10, 2025, 7:00 AM EST - 7 months ago

Candel Therapeutics Slides: Corporate Presentation

Dec 5, 2025, 11:00 AM EST - 7 months ago

Candel Therapeutics Transcript: R&D Day 2025

Dec 5, 2025, 11:00 AM EST - 7 months ago

Candel Therapeutics Press release: FY 2025

Nov 18, 2025, 3:00 AM EST - 7 months ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 4:05 PM EST - 7 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

2025-11-14T11:40:57.000Z - 7 months ago

Candel Therapeutics price target lowered to $24 from $25 at Citi

2025-11-13T13:31:40.000Z - 7 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

Nov 13, 2025, 8:25 AM EST - 7 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 13, 2025, 8:00 AM EST - 7 months ago

Candel Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Candel Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Candel Therapeutics Slides: Corporate Presentation

2025-11-04T14:10:59.000Z - 8 months ago

Candel Therapeutics announces it will deliver three presentations at SITC

Nov 4, 2025, 9:00 AM EST - 8 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 8 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

2025-10-28T11:21:24.000Z - 8 months ago

Candel initiated with an Overweight at Stephens on differentiated pipeline

2025-10-27T20:35:14.000Z - 8 months ago

Candel Therapeutics initiated with an Overweight at Stephens

2025-10-21T10:40:56.000Z - 8 months ago

Candel Therapeutics initiated with an Outperform at LifeSci Capital

2025-10-16T12:20:35.000Z - 8 months ago

Candel Therapeutics appoints Pulendran to Candel’s RAB

Oct 16, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

2025-10-14T12:31:44.000Z - 9 months ago

Candel Therapeutics enters into $130M term loan facility

TRIN

Oct 14, 2025, 8:10 AM EDT - 9 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 9 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 3, 2025, 9:05 AM EDT - 9 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:00 AM EDT - 10 months ago

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Registration statement: Registration Filing

Aug 13, 2025, 2:00 PM EDT - 11 months ago

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Jul 30, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 1 year ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 1 year ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 14, 2025, 7:20 PM EDT - 1 year ago

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 1 year ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Candel Therapeutics Annual report: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 8:30 AM EST - 1 year ago

Candel Therapeutics Transcript: Study Result

Dec 11, 2024, 8:30 AM EST - 1 year ago

Candel Therapeutics Press release: Study Result

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

minnesotafarmcountry Jun. 25 at 4:42 AM

$CADL Back to the AI trade tomorrow? Will biotech traders jump on that bandwagon again and chase at nosebleed valuations? 🤷‍♀️. Too bad for them!

0 · Reply

1Loonie2Toonie Jun. 24 at 11:09 PM

$CADL I wish we were around $15 at this stage. Maybe in a few months...

1 · Reply

Home_Skillet Jun. 24 at 10:28 PM

0 · Reply

Newageinvestor Jun. 24 at 10:12 PM

0 · Reply

Clemente4141 Jun. 24 at 9:56 PM

$CADL

0 · Reply

bad_at_stocks Jun. 24 at 9:49 PM

3 · Reply

paladinten17 Jun. 24 at 9:35 PM

1 · Reply

ShowMeThaMonay Jun. 24 at 9:27 PM

$CADL hard to tell what to do, don’t really want to add shares here. Have buys set if it drops back to 8.30 and lower. I added some long calls that I’m holding.

0 · Reply

CO145 Jun. 24 at 9:14 PM

2 · Reply

DiamondDog33 Jun. 24 at 9:12 PM

2 · Reply

PaulNipkow Jun. 24 at 8:56 PM

$CADL If the signs are any indication, I'm afraid JNJ is now truly in love with Cadl ..

2 · Reply

CO145 Jun. 24 at 8:42 PM

$CADL I really can't imagine why anyone would opt for radical prostatectomy and deal with its related issues when there is a cure. CAN-2409 will certainly take share from RP. We are talking a bigger patient population than 65k. "Sir, you can have your prostate removed and face incontinence and ED, or you can be cured with a simple shot and radiation." "Hmmm. Doc, I'll take the shot." Add another potential 65k to the mix. Whatever the penetration rate turns out to be for each patient population only means peak sales are going to be higher than what the street in modeling. Higher peak sales means higher stock price and even greater interest by BP. Just imagine a BP sales force going out in droves to educate Dr.s and convince them about the curative route vs the cut it out route. And think about how much attention a stupid tv commercial will alert the patient on their choices. BP is coming as soon as Tak opens the door.

1 · Reply

minnesotafarmcountry Jun. 24 at 8:35 PM

$CADL Gotta love this market … bought 100 MU at $992 about 2:15 and rode it to $1180 after mkt! Gee, new money 💰 … guess what I’m buying tomorrow? 😎

2 · Reply

focafoca99 Jun. 24 at 8:33 PM

$CADL voted its board directors and ratified its auditor at the June 23 annual meeting.

0 · Reply

tobeme100 Jun. 24 at 8:25 PM

$CADL About the same dollar bought @ close today? Hmm.

0 · Reply

Greyhound9 Jun. 24 at 8:18 PM

$CADL Nice day in the end, although I would have preferred to see it close above 9:30. Tomorrow is another day and maybe good news about the NSCLC. PPT is your turn tomorrow. Have a nice evening and see you tomorrow. 🙋🏼‍♂️

0 · Reply

ShadowBull3745 Jun. 24 at 8:02 PM

$CADL Another good day

0 · Reply

Yeettrader Jun. 24 at 8:01 PM

$CADL one penny below the 52wk highest daily closing price. Nice and coiled for the P3 announcement. Tomorrow pre market seems the most likely.

0 · Reply

chrundel Jun. 24 at 7:45 PM

$CADL screaming for 10$… then it’s only a few dollars off 1B market cap, at which point were only undervalued by a couple more B. Summer of CADL

0 · Reply

Xanderzzzzzzz Jun. 24 at 7:00 PM

$CADL US Prostate market alone is hugeeeeeeeee. KWYO

0 · Reply

Whiskeyunderthebed Jun. 24 at 6:36 PM

$CADL

1 · Reply

Masked__Investor Jun. 24 at 6:28 PM

$CADL will be holding to at least stock price of 60$ per share. This has not even started...

0 · Reply

Market Cap	665.29M
Revenue (ttm)	0.00
Net Income (ttm)	-38.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.34

Volume	1,477,900
Avg Vol	2,176,968
Day's Range	N/A - N/A
Shares Out	73.27M
Stochastic %K	81%
Beta	-0.49
Analysts	Strong Sell
Price Target	$19.12